NexPoint Real Estate Finance, Inc.

Second-quarter net income was $0.29 per diluted share versus $0.54 in Q2 2025. Earnings available for distribution was $0.46 per diluted share versus $0.43 in the prior-year quarter, and cash available for distribution was $0.58 versus $0.46. The regular dividend was $0.50 per share and was 1.16x covered by CAD. Book value per diluted share was $18.60, down 1.9% from Q1 2026. Guidance for Q3 2026 calls for earnings available for distribution of $0.43 per diluted share at the midpoint ($0.38 to $0.48 range) and cash available for distribution of $0.55 per diluted share at the midpoint ($0.50 to $0.60 range).

Matthew Ryan McGraner described the quarter as another period of “consistent solid execution” and said recurring earnings power is ticking up while the company remains at the top of its commercial mortgage REIT peer group on credit. He highlighted improving residential fundamentals, stronger life science leasing, and self-storage outperformance, framing the portfolio as positioned for a supply-driven recovery in residential and a widening tenant base in life science. His tone was confident and constructive, especially around the company’s ability to redeploy capital at attractive returns.

Paul Richards emphasized the quarter’s distribution metrics and balance-sheet actions. He noted net income of $0.29 per diluted share, EAD of $0.46, CAD of $0.58, and dividend coverage of 1.16x, and said the board kept the dividend at $0.50 per share for Q3. He also highlighted the $375 million Mizuho drawable term loan facility used to repay the $180 million 5.75% senior unsecured notes, with $362.2 million outstanding on the facility and a reduced net interest cost of SOFR plus 245 via the TRS, calling the structure one of the cleanest and most flexible in the sector.

Analysts focused on portfolio mix, dividend sustainability, and credit quality. On mix, management said it would like life science to be about one-third of assets in a normalized environment and residential to be around 50%, and expects some Alewife capital to come back for redeployment into residential. On the dividend, Paul Richards said the company is comfortable with CAD coverage and expects EAD and CAD to converge over time. On credit, management said multifamily and B-piece exposure have performed well, with no noted provisions or credit leaks, and life science is improving with tours up 30% or more sequentially and Q3 tracking ahead of Q2.